Novartis Institute for Tropical Diseases chooses Genedata Software Solutions |
| Tweet |
30.06.2005, Novartis Institute for Tropical Diseases chooses Genedata Software Solution for anti-infectives Research.
Genedata AG today announced a collaboration with Novartis Institute for Tropical Diseases (NITD) in Singapore involving the Genedata Phylosopher PathoLead edition to advance research in progressive infectious and parasitic disease. Genedata Phylosopher(R) will serve as an organization-wide scientific management system for proprietary data integration.
Scientists at NITD will use the software to identify and validate target candidates and to prioritize development of novel drug classes. Research at NITD focuses on Dengue fever and tuberculosis, the two most life-threatening tropical diseases. There’s no treatment for Dengue and trends suggest an epidemic could extend beyond the Developing world. The ultimate goal would be to develop an anti-viral treatment. Tuberculosis is commonly perceived to be well controlled, but more people die of it today than at any other time in history. There are no alternative treatments and no new drugs have come to market for 30 years.
Genedata Phylosopher will enable scientists at the NITD to reconstruct pathways and perform comparative genomic analysis of complex host-pathogen interactions such as human-animal infection models. By integrating experimental data from genomic, transcriptomic, proteomic and metabolomic sources with knock-out data and other results, they will explore mechanisms underlying infection and treatment-action at the molecular level. Such sophisticated analyses are essential for identifying novel targets, generating screening assays, and developing effective therapies.
Genedata’s collaborations now span oncology, CNS, metabolic diseases, predictive toxicology and biomarker discovery.
More information can be found under www.genedata.com
Scientists at NITD will use the software to identify and validate target candidates and to prioritize development of novel drug classes. Research at NITD focuses on Dengue fever and tuberculosis, the two most life-threatening tropical diseases. There’s no treatment for Dengue and trends suggest an epidemic could extend beyond the Developing world. The ultimate goal would be to develop an anti-viral treatment. Tuberculosis is commonly perceived to be well controlled, but more people die of it today than at any other time in history. There are no alternative treatments and no new drugs have come to market for 30 years.
Genedata Phylosopher will enable scientists at the NITD to reconstruct pathways and perform comparative genomic analysis of complex host-pathogen interactions such as human-animal infection models. By integrating experimental data from genomic, transcriptomic, proteomic and metabolomic sources with knock-out data and other results, they will explore mechanisms underlying infection and treatment-action at the molecular level. Such sophisticated analyses are essential for identifying novel targets, generating screening assays, and developing effective therapies.
Genedata’s collaborations now span oncology, CNS, metabolic diseases, predictive toxicology and biomarker discovery.
More information can be found under www.genedata.com
Über Novartis Pharma Schweiz AG:
Die Novartis Pharma Schweiz AG ist eine Tochtergesellschaft der Novartis Pharma AG Basel. Als eines der grössten Schweizer Pharma-Unternehmen sind wir in der Schweiz für die verschreibungspflichtigen Medikamente von Novartis verantwortlich.
Die rund 220 Mitarbeiterinnen und Mitarbeiter sind in den Bereichen des Marketings und des Vertriebs beschäftigt, beraten im Aussendienst niedergelassene Aerzte und Spital-Aerzte oder betreuen Projekte in der klinischen Forschung, der wissenschaftlichen Dokumentation und der Registrierung von neuen Medikamenten.
Die rund 220 Mitarbeiterinnen und Mitarbeiter sind in den Bereichen des Marketings und des Vertriebs beschäftigt, beraten im Aussendienst niedergelassene Aerzte und Spital-Aerzte oder betreuen Projekte in der klinischen Forschung, der wissenschaftlichen Dokumentation und der Registrierung von neuen Medikamenten.
Weitere Informationen und Links:
Newsletter abonnieren
Auf diesem Link abonnieren Sie unseren Newsletter und sind stets aktuell informiert.
Eigene News publizieren
Haben Sie eine aktuelle Firmeninformation oder ein Angebot, dass Sie hier publizieren möchten?
Auf diesem Link erfassen Sie die entsprechenden Informationen.
TOP NEWS - powered by Help.ch
Firmenneugründungen im April 2025 rückläufig - Nur 4’554 neue Unternehmen im Schweizer Handelsregister eingetragen HELP Media AG, 02.05.2025
Organspende im Aufwärtstrend - trotz mehr Ablehnungen Swisstransplant, 02.05.2025
Sexuelle und reproduktive Gesundheit und Rechte im Zeitalter von KI und Social Media Medicus Mundi Switzerland, 02.05.2025
Aktueller Jackpot: CHF 2'036'579
Teilnehmer von
